USE OF PSORALEN DERIVATIVES AND COMBINATION THERAPY FOR TREATMENT OF CELL PROLIFERATION DISORDERS

(19)

(11)

EP 3 097 108 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	07.04.2021 Bulletin 2021/14

(45)	Mention of the grant of the patent:
	04.11.2020 Bulletin 2020/45

(21)	Application number: 15740092.0

(22)	Date of filing: 23.01.2015

(51)

International Patent Classification (IPC):

C07D 493/00^(2006.01)
A61K 41/00^(2020.01)
A61K 31/4709^(2006.01)
A61K 31/37^(2006.01)

A61K 45/06^(2006.01)
A61K 31/517^(2006.01)
A61K 31/436^(2006.01)
A61P 35/00^(2006.01)

(86)	International application number:
	PCT/US2015/012669

(87)	International publication number:
	WO 2015/112850 (30.07.2015 Gazette 2015/30)

(54)

USE OF PSORALEN DERIVATIVES AND COMBINATION THERAPY FOR TREATMENT OF CELL PROLIFERATION DISORDERS

VERWENDUNG VON PSORALENDERIVATEN UND KOMBINATIONSTHERAPIE ZUR BEHANDLUNG VON ZELLPROLIFERATIONSSTÖRUNGEN

UTILISATION DE DÉRIVÉS DE PSORALÈNE ET D'UNE POLYTHÉRAPIE POUR LE TRAITEMENT DE TROUBLES DE LA PROLIFÉRATION CELLULAIRE

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

23.01.2014 US 201461930717 P

(43)	Date of publication of application:
	30.11.2016 Bulletin 2016/48

(73)	Proprietors:
	Immunolight, LLC Detroit, MI 48226 (US) Duke University Durham, NC 27705 (US)

(72)	Inventors:
	XIA, Wenle Durham, NC 27705 (US) GOODEN, David Durham, NC 27705 (US) SODERBLOM, Erik J. Durham, NC 27705 (US) TOONE, Eric J. Durham, NC 27705 (US) SPECTOR, Neil L. Durham, NC 27705 (US) BEYER, Wayne F. Detroit, MI 48226 (US) WALDER, Harold Detroit, MI 48226 (US)

(74)	Representative: Wallinger, Michael
	Wallinger Ricker Schlotter Tostmann Patent- und Rechtsanwälte Partnerschaft mbB Zweibrückenstrasse 5-7 80331 München 80331 München (DE)

(56)

References cited: :

WO-A1-89/06702
WO-A2-2004/048525
US-A- 5 116 864
US-A1- 2009 148 402
US-A1- 2011 111 018

WO-A2-93/07748
GB-A- 2 003 470
US-A- 5 556 612
US-A1- 2010 113 474
US-A1- 2013 131 429

L W-C CHOW ET AL: "Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer", BRITISH JOURNAL OF CANCER, vol. 108, no. 10, 30 April 2013 (2013-04-30), pages 1985-1993, XP055398320, GB ISSN: 0007-0920, DOI: 10.1038/bjc.2013.178
AWADA A ET AL: "Lapatinib ditosylate: Expanding therapeutic options for receptor tyrosine-protein kinase erbB-2-positive breast cancer", DRUGS OF TODAY 2011 PROUS SCIENCE ESP, vol. 47, no. 5, May 2011 (2011-05), pages 335-345, XP002772981, ISSN: 1699-4019
XIA W ET AL: "Photo-activated psoralen binds the ErbB2 catalytic kinase domain, blocking ErbB2 signaling and triggering tumor cell apoptosis", PLOS ONE 20140214 PUBLIC LIBRARY OF SCIENCE USA, vol. 9, no. 2, 14 February 2014 (2014-02-14), XP002772982, ISSN: 1932-6203

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).